An Investigation of the Succination of the Selenoproteins Thioredoxin Reductase and Glutathione Peroxidase by Lanci, Scott
University of South Carolina
Scholar Commons
Theses and Dissertations
6-30-2016
An Investigation of the Succination of the
Selenoproteins Thioredoxin Reductase and
Glutathione Peroxidase
Scott Lanci
University of South Carolina
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Other Life Sciences Commons
This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Lanci, S.(2016). An Investigation of the Succination of the Selenoproteins Thioredoxin Reductase and Glutathione Peroxidase. (Master's
thesis). Retrieved from https://scholarcommons.sc.edu/etd/3494
 An Investigation of the Succination of the Selenoproteins Thioredoxin 
Reductase and Glutathione Peroxidase 
 
by 
 
Scott Lanci 
 
Bachelor of Science 
Coastal Carolina University, 2012 
 
 
 
Submitted in Partial Fulfillment of the Requirements 
 
For the Degree of Master of Science in 
 
Biomedical Science 
 
School of Medicine 
 
University of South Carolina 
 
2016 
 
Accepted by: 
 
Norma Frizzell, Director of Thesis 
 
Chandrashekhar Patel, Reader 
 
Kenneth Walsh, Reader 
 
Lacy Ford, Senior Vice Provost and Dean of Graduate Studies
ii 
© Copyright by Scott Lanci, 2016 
All Rights Reserved.
iii 
DEDICATION 
I would like to dedicate this thesis to my parents Jeff and Rose Lanci as well as my sister 
Jennifer Lanci. My family has always given me their unwavering support as I have 
pursued my dreams. My mentor Dr. Norma Frizzell has also given me the tremendous 
opportunity to work in her laboratory to obtain my Master’s Degree at the University of 
South Carolina School of Medicine, for which I will always be grateful. 
iv 
ACKNOWLEDGEMENTS 
I would like to thank my mentor, Dr. Norma Frizzell, above all for graciously allowing 
me to work in her laboratory to pursue my Master’s Degree. I would like to give special 
thanks to Dr. Gerardo Piroli for his contributions to my project and his expertise and 
advice throughout my time working in this lab. I would also like to thank our current 
Ph.D. student Allison Manuel, our current M.S. student Lydia Proctor, and our laboratory 
technician Anna Clapper for their individual contributions to my project and for teaching 
me new laboratory techniques. 
v 
ABSTRACT
We have identified the irreversible protein modification S-(2-succino)cysteine, a 
product of the Kreb’s cycle intermediate fumarate reacting with the thiol group of 
cysteine (Cys) residues, also termed succination. Succination is increased in adipose 
tissue of diabetic mice in vivo and in adipocytes matured in high glucose medium (25 
mM) in vitro. Selenocysteine (Sec) is a less common but highly conserved amino acid 
that has major functions in redox chemistry. Sec possesses a lower pKa (~5.4) and is 
much more reactive in comparison to Cys. This project aimed to determine if succination 
occurred on Sec residues in two selenoproteins that play roles of maintaining intracellular 
redox environments and contain Sec in their active sites, thioredoxin reductase (TrxR) 
and glutathione peroxidase (GPx). We hypothesized that increased fumarate levels will 
lead to the succination of Sec and causing decreased enzymatic activity for each enzyme.  
Two cellular models were used with elevated fumarate levels: (1) 3T3-L1 
adipocytes matured in high glucose medium (25 mM) to mimic diabetic conditions and 
(2) 3T3-L1 fibroblasts where fumarase was knocked-down (Fh k/d) to mimic fumarase 
deficient cancers. As a positive control to demonstrate the ability to succinate TrxR in 
vitro, recombinant TrxR1 was incubated with the reactive fumarate ester, dimethyl 
fumarate (DMF). After analysis, a ~56% reduction in activity was detected due to 
succination of an active site residue, which was confirmed by mass spectrometric 
analyses.  
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Unexpectedly, TrxR activity was found to be significantly increased in 3T3-L1 
adipocytes matured in 25 mM glucose compared to 5 mM glucose, despite no changes in 
protein levels. No statistically significant changes in TrxR activity were found in Fh k/d 
3T3-L1 fibroblasts compared to controls. GPx activity was found to be significantly 
reduced in 3T3-L1 adipocytes matured in high glucose with no changes in levels of GPx 
protein. GPx activity was also analyzed in Fh k/d 3T3-L1 fibroblasts, however no 
significant changes were detected. 
Overall, the results demonstrate that TrxR can be modified readily by reactive 
fumarate esters, leading to decreased enzymatic activity. However, endogenously 
produced fumarate does not appear to significantly contribute to TrxR or GPx 
modification in the models studied. 
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 Succination of Proteins 
The amino acid cysteine (Cys) plays unique biological roles in nature due to its 
chemical structure. Cysteine contains a thiol group with a pKa ~9.5 (1) when exposed on 
the surface of a protein, but its pKa can be as low as ~3-4 when located within the active 
site of an enzyme (2). Therefore the thiol group is readily deprotonated in physiological 
conditions and can be considered one of the most reactive residues found in peptides (3). 
This reactivity makes cysteine a strong nucleophile and the thiolate (S
-
) is susceptible to 
increased oxidation to the reversible sulfenic acid (SOH) (4), or further to the irreversible 
sulfinic (S(O)2H) and sulfonic acids (S(O)3H) (5). Sacrificial thiol oxidation is known to 
play an important role in the cellular response to oxidative stress, and partially oxidized 
thiols are often functionally regenerated by the glutathione system. 
Alterations in cellular metabolism may lead to increases in oxidizing 
intermediates, but other metabolic intermediates are also capable of chemically 
modifying cysteine thiolates. Recently, the modification of cysteine residues in proteins 
by the Kreb’s cycle intermediate fumarate has been described. In the case of this 
modification, known as protein succination, fumarate undergoes a Michael addition 
reaction to form a thioether bond with the thiol group of cysteine yielding a product 
termed S-(2-succino)cysteine (2SC) (6, 7) (Figure 1.1). Protein succination is an 
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irreversible, non-enzymatic post-translational modification of proteins that may result in 
alteration of the protein structure or function. The 2SC modification has been detected on 
over 50 proteins expressed by mouse adipocytes (6), but has also been detected in human 
plasma albumin, consisting of 3.5% of the total protein (7), in skin collagen and skeletal 
muscle proteins (2). Reduced functionality following protein succination has been 
demonstrated for cytosolic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
mitochondrial aconitase, with both exhibiting decreased enzymatic activity (8, 9). 
GAPDH is a glycolytic enzyme that, when inhibited during hyperglycemic conditions, is 
linked to the development of diabetic complications such as vascular endothelial damage 
(10). Aconitase is a Kreb’s cycle enzyme responsible for isomerization of citrate to 
isocitrate and its impaired activity results in a disruption in mitochondrial metabolism (9).  
The adipocyte hormone adiponectin circulates in plasma as high molecular weight 
oligomers and stimulates fatty-acid oxidation in muscle and in the liver (11). Adiponectin 
is also a target of succination and this inhibits its oligomerization, preventing its secretion 
into plasma where it can circulate to its target receptors throughout the body (12). This 
fact is significant considering that high molecular weight forms of adiponectin are 
decreased in the plasma of Type 2 diabetics. 
In the adipocyte, protein succination is a direct effect of mitochondrial stress 
caused by elevated extracellular glucose levels when cellular metabolism is increased.  
These conditions lead to an increase in ATP/ADP ratios and an accumulation of ATP. 
This accumulation inhibits the mitochondrial electron transport chain through respiratory 
control, increasing the mitochondrial membrane potential (Δψm) and NADH/NAD
+
 ratio, 
leading to an accumulation of fumarate due to the inhibition of NAD
+–dependent Kreb’s 
3 
cycle enzymes (13) (Figure 1.2). Increased levels of succinated proteins have been 
demonstrated in both 3T3-L1 adipocytes matured in high glucose medium (30 mM) 
versus normal glucose medium (5 mM), and in the adipose tissue of diabetic db/db mice 
(13, 14). Beyond the adipocyte, increased succination has also been detected in hereditary 
leiomyomatosis and renal cell cancer (HLRCC) where the enzyme fumarase, responsible 
for converting fumarate to malate, is deficient or mutated, leading to a pronounced 
increase in succination in these tumors (15). In fact, the immunohistochemical detection 
of succinated proteins is used clinically as a biomarker for fumarase deficiency (6, 16, 17, 
18). Increased levels of protein succination have most recently been described in a 
mitochondrial encephalopathy associated with a defect in mitochondrial oxidative 
phosphorylation, where increased succination of select proteins may play a role in 
defective neuronal function (19). 
1.2 Selenocysteines 
 In general, there are twenty abundant amino acids found in nature. However a less 
common, but highly conserved amino acid, selenocysteine (Sec), plays a critical role in a 
range of cellular functions. Often coined the “21st amino acid” (20), Sec has a similar 
chemical structure to the more common amino acid cysteine, with the exception of a 
selenium atom in place of sulfur. The two amino acids have different chemical properties, 
as selenocysteine has a much lower pKa value (~5.4) compared to cysteine (~9.5) (21).  
This lower pKa of Sec results in the selenol group (SeH) being deprotonated in 
physiological pH ranges (6.5-7.5), yielding the selenolate (Se
-
) form, and thus Sec is 
more reactive than Cys (22). Sec is inherently a strong nucleophile, and therefore is often 
found in the active site of enzymes that play a role in redox reactions.  
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 Selenoproteins are defined as proteins that contain one or more Sec in their 
sequence. During protein translation, Sec is encoded by the UGA mRNA codon, which 
under normal circumstances will terminate protein synthesis (23). However the mRNAs 
for selenoproteins contain a selenocysteine insertion sequence (SECIS), a stem-loop 
structure that resides downstream from the UGA codon and allows the Sec-specific 
translation machinery to associate with the ribosome (20). Without the SECIS, the protein 
will be prematurely truncated and no Sec will be incorporated. 
 Selenoproteins exist in all three domains of life and currently over 50 different 
families of these proteins have been identified (24). Humans contain 25 known genes that 
encode selenoproteins (23), having functions from redox signaling, protection from 
reactive oxygen species (ROS), protein folding and thyroid hormone metabolism. The 
wide range of biological functions that selenoproteins possess, particularly in redox 
biology, is dependent upon the chemical properties of selenocysteine (24). These proteins 
are widely distributed throughout the human body, some being ubiquitous while others 
are tissue and organelle specific (25). Many selenoproteins are proposed to be essential 
for normal brain development and therefore highly expressed in nervous system, and 
deficits in some selenoproteins have been linked to an assortment of neurological 
disorders in mice (26, 27, 28). 
1.3 Oxidative Stress in Disease 
 Reactive oxygen species (ROS) can arise in the cell from mitochondrial oxidative 
metabolism, or from cellular responses to xenobiotics, cytokines or microbial invasion 
(29). The most abundant forms of these species found in the cell are hydrogen peroxide 
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(H2O2) or superoxide (O2
-
). Under physiological concentrations, ROS may function as 
regulators of intracellular signaling pathways, primarily through the oxidative 
modification of specific cysteine residues on target proteins (30). In some cases, ROS 
have significant physiological roles, for instance they are involved in the regulation of 
cellular processes such as inflammation through modification of Nuclear Factor kappa B 
thiol groups (31, 32), and the response to growth factor (GF) stimulation (30). 
Maintaining an appropriate concentration of ROS is critical for normal cellular function, 
and oxidant mediated stress may develop when the production of ROS increases. 
Therefore antioxidant systems such as the thioredoxin and glutathione systems must also 
be properly regulated to maintain homeostatic environments. The abundance of Sec 
containing selenoproteins in the antioxidant response system emphasizes the roles of 
these proteins in dealing with the balance of intracellular ROS. 
 Oxidative stress is defined as a disruption in the balance between the production 
of ROS and antioxidant defenses (33). Therefore, oxidative stress can arise when there is 
an increase in the amount of ROS produced and/or a decrease in the activity or levels of 
antioxidants (34). In diseases such as diabetes mellitus, hyperglycemic conditions lead to 
a pronounced increase in the production of ROS, disrupting the physiological balance 
between oxidants and antioxidants, ultimately causing oxidative stress and cellular 
damage (35). Adipocytes exposed to hyperglycemic conditions in vitro and in vivo are 
associated with increased levels of ROS production, a pronounced inflammatory response 
and insulin resistance (36). Insulin resistance in skeletal muscle has been linked to 
persistently oxidized redox environments caused by increased mitochondrial ROS 
production during high fat diet feeding (37). The thioredoxin system, specifically 
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thioredoxin reductase 1 (TrxR1), has been shown to be critical for neutralizing glucose-
derived H2O2 under high glucose conditions in vitro (38). 
1.4 Thioredoxin Reductase 
 The thioredoxin system, consisting of thioredoxin (Trx), thioredoxin reductase 
(TrxR) and nicotinamide adenine dinucleotide phosphate (NADPH), is ubiquitous in all 
cellular organisms (39). This crucial system provides redox regulation of protein function 
and signaling through its action of reducing cellular thiols (39). Wide regulation of gene 
expression through redox control of transcription factors constitutes one of the major 
roles of the thioredoxin system (40). Trx, in its reduced form, serves as a hydrogen donor 
to catalyze the reduction of disulfide bonds found in the redox-sensitive proteins such as 
apoptosis signal-regulated kinase 1 (ASK1), thioredoxin interacting protein (Txnip), 
phosphatase and tensin homolog (PTEN), and other targets that function in the 
modulation of cellular processes such as inflammation, metabolism, development, 
proliferation and migration (41). Through maintaining intracellular redox environments, 
this system also provides a major defense against oxidative stress and the prevention of 
apoptosis (42). 
 Thioredoxin reductase is also a critical part of the thioredoxin system as its 
primary function is to maintain the reduced form of Trx through its catalytic cycle (39) 
(Figure 1.3). TrxR is a monomeric selenoprotein, with the active site Sec residue located 
penultimate to the C-terminal glycine of the protein (40, 43). The N-terminal region of 
TrxR is an FAD (flavin adenine dinucleotide)-binding domain, which is responsible for 
the transfer of reducing equivalents in the catalytic cycle (44). During TrxR catalysis, 
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electrons are transferred from NADPH to the TrxR-bound FAD, which subsequently 
transfers electrons to reduce the active site Cys-Sec selenylsulfide bond (40, 44). The 
importance of the active site Sec during the TrxR catalytic cycle is highlighted when this 
residue is substituted with Cys, as this does not result in the formation of an active site 
disulfide bond and the Cys mutant enzyme shows almost no activity (38, 40, 43). Three 
mammalian forms of TrxR have been identified: the cytosolic TrxR1, the mitochondrial 
TrxR2, and the testis-specific TrxR3 (40), with the most abundant isoforms being TrxR1 
and TrxR2.  
In its reduced form, TrxR has the ability to directly reduce other substrates inside 
the cell, both proteins and small molecules such as vitamin K, alloxan and lipoic acid 
(40). As previously mentioned Sec has a pKa ~5.4 and will be ionized under 
physiological pH ranges. The reactivity of Sec and its exposed location on TrxR leaves 
the enzyme susceptible to modification at the active site, rendering it incapable of 
reductase activity. Modification of TrxR has previously been demonstrated in vitro by 
exogenous electrophiles where the Sec residue and several other Cys residues were 
irreversibly modified (45, 46). 
1.5 Glutathione Peroxidase 
 The glutathione system consists of the enzymes glutathione (GSH), glutathione 
reductase (GR), glutathione peroxidase (GPx), and the hydrogen donor NADPH. GSH 
contains a thiol group in the form of a cysteine residue and plays a major role in the 
cellular antioxidant response through either the direct reduction of reactive 
oxygen/nitrogen species (ROS/RNS), or by acting as a cofactor for other enzymes (47). 
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The reduced form of glutathione (GSH) becomes oxidized to GSSG following the 
reduction of cellular proteins or the neutralization of hydrogen peroxide (H2O2). This 
system is considered to be the back-up for the thioredoxin system that also serves to 
protect from oxidative damage, as previously described. 
 Glutathione peroxidase is a key selenoprotein in this system’s regulation of redox 
environments, containing a Sec residue in its active site. The properties of Sec allow GPx 
to function as a strong reducing agent and it is involved in the reduction of hydrogen 
peroxides, organic hydroperoxides (e.g. cumene hydroperoxide) and lipid peroxides from 
fatty acid radicals (24). In the catalytic cycle for the neutralization of H2O2, the selenolate 
(Se
-
) group reacts with H2O2 to form selenic acid (SeOH), which is subsequently reduced 
back to selenol (SeH) by 2 GSH, yielding GSSG and water (48, 49, 50, 51) (Figure 1.4). 
GSSG is reduced by the enzyme glutathione reductase through the transfer of hydrogen 
from NADPH, recycling the system and allowing it to repeat its redox activity. The first 
isoform of GPx (GPx1) was the first human selenoenzyme to be discovered (52). There 
are a total of 8 identified isoforms of this enzyme; however GPx1 and GPx4 are the most 
abundant and ubiquitously expressed isoforms in the cell (51).  
The neutralization of H2O2 allows GPx1 to maintain the balance between the 
required concentrations of ROS that play physiological roles and the higher 
concentrations that lead to cellular damage (53). GPx4 has a more specialized function of 
protection of membranes from lipid peroxidation directly by hydroperoxides found inside 
of membranes; a function that enables this isoform of the enzyme to be involved in the 
attenuation of oxidative stress-induced apoptosis (24, 51). Alterations in the levels or the 
activity of GPx can lead to abnormal levels of intracellular ROS and these changes have 
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been linked to cardiovascular disease and diabetes (53). There are no known specific 
inhibitors of GPx, however oxidative modification of thiols and selenols represents the 
most characterized modification of this enzyme (53).  
1.6 Research Hypothesis and Aims 
Due to the chemical nature of selenocysteine and its predicted higher reactivity at 
physiological pH when compared to cysteine, I hypothesize that Sec is susceptible to 
succination when fumarate levels are elevated. Preliminary experiments in our lab have 
demonstrated that free amino acid Sec can be succinated by fumarate following in vitro 
incubation (unpublished data). Although this in vitro experiment does not account for the 
variable factors that can affect the reactivity of a protein, it provides a foundation for the 
aims of this thesis further described in the hypothesis. The fact that lower pKa residues in 
proteins may be more vulnerable to this modification has been demonstrated following 
the identification of succination of Parkinson disease protein 7 (Park7) on an active site 
Cys that possesses an unusually low pKa (~5.4) (16). In this thesis I will examine the 
succination of the selenoproteins thioredoxin reductase and glutathione peroxidase. Due 
to the presence of Sec in the active site of these enzymes, irreversible modification of this 
residue is predicted to inhibit the enzyme. As a consequence, the resulting decreased 
activity may leave the cell more vulnerable to redox active species. The exposed location 
of Sec on the C-terminus of TrxR makes this protein particularly interesting as a 
candidate for succination.  
Two different cell culture models will be used in this investigation; (1) adipocytes 
matured in high glucose medium to model diabetic conditions (versus controls in normal 
10 
glucose medium), or (2) fumarase knockdown in fibroblasts to model fumarase-deficient 
cancers, creating a model of enhanced succination. I will specifically examine the activity 
and protein levels of thioredoxin reductase and glutathione peroxidase in both of these 
cell models of elevated endogenous fumarate. 
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Figure 1.1: Protein succination reaction mechanism. Fumarate undergoes a Michael 
addition reaction to form a thioether bond with the thiol group of cysteine residues, 
yielding a product termed S-(2-succino)cysteine (2SC). Protein succination is an 
irreversible, non-enzymatic post-translational modification of proteins that may result in 
alteration of the protein structure or function. 
12 
 
Figure 1.2: Glucotoxicity driven mitochondrial stress increases protein succination. 
In the adipocyte, protein succination is a direct effect of mitochondrial stress caused by 
elevated extracellular glucose levels when cellular metabolism is increased. These 
conditions lead to an increase in ATP/ADP ratios and an accumulation of ATP. This 
accumulation inhibits the mitochondrial electron transport chain through respiratory 
control, and increasing the mitochondrial membrane potential (Δψm) and NADH/NAD
+
 
ratio, leading to an accumulation of fumarate due to the inhibition of NAD
+–dependent 
Kreb’s cycle enzymes. Elevated levels of intracellular fumarate lead to the succination of 
protein thiols. 
13 
 
Figure 1.3: The Thioredoxin system. The thioredoxin system consists of thioredoxin 
(Trx), thioredoxin reductase (TrxR) and the hydrogen donor nicotinamide adenine 
dinucleotide phosphate (NADPH). This ubiquitous system provides redox regulation of 
protein function and signaling through its action of reducing cellular thiols. TrxR is a 
selenoprotein containing a selenocysteine (Sec) in its active site, and it is responsible for 
reducing the disulfide bond in Trx. 
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Figure 1.4: The Glutathione system. The glutathione system consists of the enzymes 
glutathione (GSH), glutathione reductase (GR), glutathione peroxidase (GPx), and the 
hydrogen donor nicotinamide adenine dinucleotide phosphate (NADPH). GSH contains a 
thiol group in the form of a cysteine residue and plays a major role in the cellular 
antioxidant response through either the direct reduction of reactive oxygen/nitrogen 
species (ROS/RNS), or by acting as a cofactor for other enzymes such as GPx. GPx is a 
scavenging selenoprotein containing a selenocysteine (Sec) in its active site, and it plays 
vital protective roles inside the cell through its function of reducing damaging species 
such as hydrogen peroxide (H2O2), organic peroxides and lipid peroxides. 
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CHAPTER 2 
THE EFFECTS OF DIMETHYL FUMARATE (DMF) AND FUMARATE 
ON THIOREDOXIN REDUCTASE 1
2.1 Introduction 
 Multiple sclerosis (MS) is an inflammatory disease that results in the 
demyelination and loss of axons in the central nervous system (CNS) (54). The disease 
affects approximately one in every thousand Americans; with females being affected 
twice as often as males (55, 56). Tecfidera
®
 is a recently approved drug used to treat 
relapsing-remitting MS (RRMS), a form of the disease characterized by attacks of 
worsening neurological function, followed by partial or complete recovery periods (57). 
The primary active component of Tecfidera
®
 is dimethyl fumarate (DMF), a more 
reactive fumarate ester that is more easily absorbed and has better bioavailability than 
fumarate when administered orally (58, 59). DMF is also considered both safe and 
effective in the treatment of psoriasis, where it has been approved for use in Europe for 
over a decade (60). After ingestion, intracellular esterases rapidly hydrolyze DMF to the 
bioactive metabolite monomethyl fumarate (MMF) (58, 61). The efficacy of DMF 
treatment was tested in two randomized, double-blind, placebo-controlled clinical trials 
with RRMS patients and resulted in significantly reduced lesions (permanent axonal 
damage/loss), confirmed by magnetic resonance imaging (MRI) in those individuals who 
received the drug (58, 62, 63, 64, 65).  
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DMF promotes therapeutic cytoprotection in treating RRMS through the 
activation of the nuclear factor (erythyroid-derived)-like-2 (Nrf2) pathway, a 
transcription factor that induces the upregulation of antioxidant proteins (66, 67). After 
DMF is metabolized to MMF, it reacts with a Cys residue on the Nrf2-bound Kelch-like 
ECH-associated protein 1 (Keap1), leading to the stabilization of Nrf2 and its 
translocation to the nucleus where it binds the antioxidant response element (ARE) and 
promotes the transcription of its target antioxidant genes such as gamma-
glutamylcysteine synthetase (synthesizes glutathione (GSH))  and thioredoxin reductase 1 
(TrxR1) (68, 69). DMF/MMF readily reacts with the cysteine thiol of GSH, one of the 
first described targets of the drug, causing levels to be depleted and strongly inducing the 
anti-inflammatory stress protein heme oxygenase 1 (HO-1) (70, 71). DMF also 
suppresses pro-inflammatory genes by inhibiting nuclear factor kappa B, and combined 
with the anti-oxidative targets of Nrf2 activation, these responses are believed to slow the 
demyelination and neurodegeneration associated with MS by causing a decrease in 
circulating T cells and CD4
+
 cells involved in inflammation (62, 66, 72, 73). 
 Despite the efficacy of DMF treatment in MS patients and the increased quality of 
life observed after clinical trials, the drug is also known to cause side effects such as 
gastrointestinal discomfort, nausea and flushing severe enough for ~10% of patients to 
discontinue use (73). The presence of these side effects and the inherent reactivity of 
fumarate esters would suggest that there are other cellular targets that are also being 
modified. Our laboratory has recently confirmed that DMF and its metabolite MMF 
result in the succination of multiple proteins in 3T3-L1 mouse adipocytes treated with 
DMF (74).  Pronounced increases in succinated Cys residues were also identified 
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following immunoblotting and LC-MS/MS analysis of porcine tubulin treated with DMF, 
and increased succination prevented its polymerization (75). 
 As previously mentioned, the Cys-Sec residues in the active site of TrxR reside on 
the exposed C-terminal region of the protein (Figure 2.1), suggesting this region of TrxR 
may be a likely target of DMF modification. In this study I investigated the succination of 
TrxR by DMF, hypothesizing that (1) I would demonstrate the vulnerability of this 
enzyme’s active site to modification and, (2) identify a novel protein modified by DMF. 
These studies would also determine if the same active site residues might also be 
susceptible to succination by the less reactive but endogenously produced metabolite 
fumarate. 
2.2 Results 
 To determine the effects of DMF on TrxR activity in vitro, rat recombinant 
thioredoxin reductase 1 (TrxR1) protein was reduced with NADPH prior to incubations 
with 0, 5, 50 and 100 µM DMF for 1 hour at room temperature. The pre-reduction step of 
TrxR by NADPH is necessary since the active site Cys-Sec forms a selenylsulfide bond 
(Figure 1.3) (46), needs to be reduced so that the selenolate (Se
-
) can react with 
electrophiles. The enzymatic activity was measured following the reduction of 5 mM 
5,5’-dithio-bis(2-dinitrobenzoic acid) (DTNB) and expressed as the rate of molar 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mg protein (mean 
 S.E.M) (Figure 2.2). Incubations with 50 and 100 µM DMF exhibited activities (mean 
 S.E.M.) of 9.98  0.41 and 5.71  0.24 µmol/min/mg respectively, compared to the 
control activity of 13.74  0.54 µmol/min/mg. These activities were statistically 
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significant decreases compared to the control; a ~27% average decrease in activity for the 
50 µM group and ~56% average decrease in the 100 µM group. 
Proteomic analysis using high-resolution mass spectrometry (MS) was performed 
on rat recombinant TrxR1 incubated in 100 µM DMF for 1 hour at room temperature to 
confirm succination and also identify specific succinated residues. The protein was 
digested with trypsin (cleaves after lysine and arginine residues), generating a series of 
peptides that were distinguished based on the mass/charge ratio (m/z). The potential 
alteration in peptide mass due to the addition of MMF or DMF protein adducts on Cys or 
Sec residues was then considered. This analysis revealed that DMF modified 3 of the 13 
Cys residues on the protein; Cys177 was modified by MMF, Cys189 was modified by 
either MMF or DMF, and Cys475 was modified by MMF. All of these cysteine 
containing peptides were detected with increases in mass of 130 Da (mass of MMF) or 
144 Da (mass of DMF). The masses detected were consistent with the Michael addition 
of free cysteine sulfhydryl group across the double bond of MMF or DMF. Despite the 
immediate identification of several succinated cysteine containing peptides, I was 
particularly interested in the N-terminal peptide containing the Sec residue. Further 
MS/MS analysis and fragmentation of the specific mass attributed to the terminal peptide 
sequence (SGGDILQSGCUG) confirmed MMF modification of this peptide. However, 
while the ion fragments detected confirmed the identity of the succinated peptide, they 
did not allow the assignment of the specific succinated site, i.e. it was either one of active 
site residues Cys497 or U498 (Table 2.1). An MS/MS spectrum of the peptide 
([MH+3]
3+
, 458.50 Daltons) (Figure 2.3) shows the 5 fragments of the parent ion 
identified and the corresponding masses, confirming sequence identity. The fragments 
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detected are b ions, indicating they were generated from the fragmentation at the N-
terminus of the peptide. The data confirms that the active site Sec containing peptide was 
succinated, amongst additional succinated sites, in association with the reduction in 
enzymatic activity. 
 After successfully demonstrating reduced activity of TrxR1 in vitro by 
succination of active site residues after DMF treatment, the effects of fumarate on the 
enzymatic activity were investigated. Recombinant rat TrxR1 protein was pre-reduced 
with NADPH prior to incubations with 0, 10, 50 or 100 mM fumarate for 6 hours at room 
temperature. TrxR activity was measured and expressed as the rate of molar NADPH 
oxidation per mg protein (mean  S.E.M). However there was no detectable reduction in 
enzymatic activity with any fumarate concentration compared to the control group 
(Figure 2.4). Additional experiments were performed at a range of different incubation 
times and temperatures; however detectable decreases in TrxR activity could not be 
established (data not shown). 
TrxR activity and protein levels were next investigated in the lysates of N1E-115 
neuronal cells after treatment with DMF. The cells were treated with a 100 µM DMF for 
either 3 hours or 24 hours prior to harvesting protein, and compared to a control group 
where no DMF was added. However, reliable data for TrxR activity could not be 
generated for this model. The TrxR activity assay utilizes a TrxR-specific inhibitor, 
where the total thiol-reducing activity (samples without inhibitor) is measured in parallel 
with the non-TrxR thiol reducing activity (samples containing TrxR inhibitor). TrxR 
activity can be calculated by subtracting the non-TrxR activity (inhibitor present) from 
the total thiol-reducing activity (inhibitor not present). Two separate attempts at this 
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assay were performed however samples containing the TrxR inhibitor consistently 
displayed higher activities than the non-inhibited samples, resulting in negative values for 
TrxR activity. In the absence of TrxR activity, the total protein levels of TrxR1 and 
TrxR2 were analyzed in the control vs. 3 hour DMF vs. 24 hour DMF by 
immunoblotting, however no apparent changes in the levels of the cytoplasmic TrxR1 
(Figure 2.5, TrxR1 panel, lanes 1-5 vs. lanes 6-10 vs. lanes 11-15) or mitochondrial 
TrxR2 (Figure 2.5, TrxR2 panel) were detected between the three groups. The levels of 
-tubulin (DM1A) were used to demonstrate equal protein loading (Figure 2.5, DM1A 
panel). 
2.3 Discussion 
 The ability of DMF to modify TrxR and significantly reduce its activity was 
confirmed through enzymatic activity assays and MS proteomic analysis. This is the first 
time that succination has been identified as a modification of this enzyme and these data 
provide new information on the mechanism of action of this drug. The reactivity of DMF 
is also highlighted by these findings, as the protein was modified with reduced activity 
after only 1 hour incubation at room temperature, and these results served as proof of 
concept for the susceptibility of TrxR to succination. Although MS/MS analysis could 
not confirm succination of the particular succinated residue in the active site (Cys497 or 
Sec498, Table 2.1), the observed decrease in enzymatic activity was most likely due to 
the modification of either active site residue by DMF, since they are both critical for the 
overall reaction mechanism (Figure 1.3). One might postulate that the much higher 
reactivity of Sec compared to Cys would cause Sec to be more favorably modified. 
Despite the uncertainty surround the particular active site residue was modified by DMF, 
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the data clearly demonstrates that a reduction in enzymatic activity could be observed 
after modification of either of these residues. Future experiments may be able to confirm 
the precise location of modification through further MS analysis to determine if Sec 
specifically has greater reactivity with this electrophile. 
Although succination and decreased TrxR activity was observed in vitro for 
recombinant protein treated with DMF, the inability to successfully measure TrxR 
activity in a cell treated with DMF does not allow further conclusions to be drawn 
regarding DMF effects on intracellular TrxR. The TrxR activity assay utilizes a TrxR 
inhibitor (sodium aurothiomalate) that allows other non-TrxR enzymatic reductions of 
DTNB to be subtracted from the total activity measured. Two activity experiments were 
performed on N1E-115 cell samples where groups with the inhibitor present abnormally 
resulted in higher activities in comparison to where the inhibitor was not present. This did 
not allow a positive value of TrxR activity to be calculated for these samples. 
This was disappointing since it might be expected that decreased TrxR activity, 
even transiently, in the cell might be due to the chemical modification of the enzyme by 
DMF treatment. We chose to examine the effect of DMF in a neuronal cell that was 
already available in our laboratory for other studies. Since DMF is used to treat RRMS, 
any alterations in TrxR activity (whether transient or prolonged) might assist in 
explaining an aspect of the beneficial or side effects of this drug. We would hypothesize 
that DMF treatment would reduce enzymatic activity, prompting an increase in oxidative 
stress that would result in Nrf2 activation and an increased production of cellular 
antioxidant proteins (see Chapter 2 Introduction). Modification of TrxR by DMF may be 
a transient and necessary component of inducing a stronger and improved antioxidant 
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balance in the cells. Immunoblotting of the protein lysates from the treated cells  
demonstrated  that neither levels of TrxR1 nor TrxR2 had changed in the control or 
DMF-treated groups (Figure 2.5, TrxR1 and TrxR2 panels). However, due to the inability 
to measure TrxR activity in these cells, the protein levels cannot be correlated with 
enzymatic activities at this time. Therefore, we look forward to future experiments 
involving this cellular model again while utilizing an alternative commercially available 
TrxR activity assay to determine the time dependency of DMF-induced decreases in 
enzymatic activity. Overall, the preliminary investigations in the studies described 
confirmed that fumarate, at least a reactive fumarate ester, could modify the active site of 
TrxR. 
 In contrast, the inability to detect changes in the recombinant TrxR1 activity after 
treatment with fumarate may be due to the decreased reactivity of this metabolite versus 
DMF. Despite performing repeated experiments with varying incubation times and 
temperatures, consistent changes in TrxR activity could not be detected. It may also be 
the case that succination of this protein by fumarate is not detectable in this in vitro time 
frame. The results of these experiments led me to conclude that I should examine the 
effects of elevated fumarate levels on TrxR in cellular models. Cells can provide a more 
suitable environment for proteins to be exposed to endogenously produced fumarate for 
longer periods of time, and these conditions could provide a better environment to 
observe the succination of TrxR. 
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Figure 2.1: Rat Thioredoxin Reductase 1 (TrxR1) protein sequence. Protein sequence 
for rat TrxR1 (P089049). Active site Cys (C) and Sec (U) are underlined at C-terminus of 
protein. Source: www.uniprot.org 
        10         20         30         40         50
MNDSKDAPKS YDFDLIIIGG GSGGLAAAKE AAKFDKKVMV LDFVTPTPLG 
        60         70         80         90        100
TRWGLGGTCV NVGCIPKKLM HQAALLGQAL KDSRNYGWKL EDTVKHDWEK 
       110        120        130        140        150
MTESVQNHIG SLNWGYRVAL REKKVVYENA YGKFIGPHKI MATNNKGKEK 
       160        170        180        190        200
VYSAERFLIA TGERPRYLGI PGDKEYCISS DDLFSLPYCP GKTLVVGASY 
       210        220        230        240        250
VALECAGFLA GIGLDVTVMV RSILLRGFDQ DMANKIGEHM EEHGIKFIRQ 
       260        270        280        290        300
FVPTKIEQIE AGTPGRLKVT AKSTNSEETI EDEFNTVLLA VGRDSCTRTI 
       310        320        330        340        350
GLETVGVKIN EKTGKIPVTD EEQTNVPYIY AIGDILEGKL ELTPVAIQAG 
       360        370        380        390        400
RLLAQRLYGG STVKCDYDNV PTTVFTPLEY GCCGLSEEKA VEKFGEENIE 
       410        420        430        440        450
VYHSFFWPLE WTVPSRDNNK CYAKVICNLK DNERVVGFHV LGPNAGEVTQ 
       460        470        480        490 
GFAAALKCGL TKQQLDSTIG IHPVCAEIFT TLSVTKRSGG DILQSGCUG
Source from <http://www.uniprot.org/uniprot/O89049> 
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Figure 2.2: The effects of dimethyl fumarate (DMF) on TrxR activity in vitro. TrxR 
activity for rat recombinant TrxR1 protein (1.5 µg) incubated with 0, 5, 50 and 100 µM 
DMF for 1 hour at room temperature (n=3). Activity is expressed as the rate of molar 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mg protein (mean 
 S.E.M). Statistically significant differences in enzymatic activity were found in samples 
incubated in 50 and 100 µM DMF compared to the control group (*P<0.001). 
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Figure 2.3: MS/MS spectrum of DMF-incubated TrxR1 terminal peptide sequence. 
The MMF modification was found on one of the active site residues Cys497 or Sec498. 
1.5 µg purified rat recombinant TrxR1 samples were incubated in 100 µM DMF for 1 
hour at room temperature and resolved by SDS-PAGE before bands were excised and 
digested with trypsin before high-resolution mass spectrometry (MS) analysis. The 
terminal peptide sequence (SGGDILQSGCUG, detected mass [M+3H]
+3
=458.50 
Daltons) was analyzed using MS/MS where a total of 5 fragments were identified 
corresponding to the MMF modification of either Cys497 or Sec498. 
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Figure 2.4: The effects of fumarate on TrxR activity in vitro. TrxR activity of rat 
recombinant TrxR1 protein (1.5 µg) incubation with 0, 10, 50 and 100 mM fumarate for 
6 hours at room temperature (n=3). Activity is expressed as rate of molar nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidation per mg protein (mean  S.E.M). No 
statistically significant differences in TrxR activity were found between the groups. 
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Figure 2.5: TrxR protein levels in N1E-115 cells treated with DMF. N1E-115-1 
neuroblastoma cells were treated with dimethyl fumarate (DMF) either 3 hours (lanes 6-
10) or 24 hours (lanes 11-15) prior to protein harvest, and compared to a control group 
(lanes 1-5) where no DMF was present. Western blotting was performed on the 
cytoplasmic lysates used to analyze protein levels of TrxR1 and TrxR2 in each group. 
Levels of -tubulin (DM1A) were used to demonstrate equal protein loading. Molecular 
weight markers (kDa) are on the left. 
 2
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Table 2.1: Mass Spectrometric data of TrxR1 peptides modified by MMF or DMF. Purified rat recombinant TrxR1 samples were 
incubated in 100 µM DMF for 1 hour at room temperature and resolved by SDS-PAGE before bands were excised and digested with 
trypsin before high-resolution mass spectrometry (MS) analysis. Initial analysis identified a total of 3 modified Cys residues; Cys177 
was modified by MMF, Cys189 modified by MMF and DMF, and Cys modified by MMF. Further MS/MS analysis of the terminal 
peptide sequence (SGGDILQSGCUG) revealed the MMF modification on one active site residue, either Cys497 or Sec498. 
C
PE
=pyridyl ethylated cysteine, PSM=peptide spectral matches (indicating the number of times the peptide was detected). 
 
 
Peptide Sequence Swiss Prot #
Monoisotopic Mass 
(Da)
Modification Sites PSMs
YLGIPGDKEYC
MMF
ISSDDLFSLPYC
PE
PGK 089049;Q5U344 3115.43 C177 5
YLGIPGDKEYC
PE
ISSDDLFSLPYC
MMF
PGK 089049;Q5U344 3115.43 C189 5
YLGIPGDKEYC
PE
ISSDDLFSLPYC
DMF
PGK 089049;Q5U344 3129.44 C189 5
QQLDSTIGIHPVC
DMF
AEIFTTLSVTK 089049;Q5U344 2745.40 C475 2
SGGDILQSGC
PE
U
MMF
G - 1373.47 U498 -
SGGDILQSGC
MMF
U
PE
G - 1373.47 C497 -
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CHAPTER 3 
THE EFFECTS OF ELEVATED FUMARATE LEVELS ON 
THIOREDOXIN REDUCTASE
3.1 Introduction 
 As described in Chapter 1, thioredoxin reductase (TrxR) contains Cys and Sec 
residues in the active site that interchange between a selenenylsulfide and selenolthiol 
motif during the catalytic cycles of this enzyme. TrxR is critical for the reduction of the 
thioredoxins (Trx) and the modulation of cellular oxidant status; therefore any 
compounds that inhibit TrxR are likely to perturb its reductive functions. The 
modification of TrxR has previously been demonstrated in vitro by the electrophiles 4-
hydroxy-2-nonenal (a product of lipid peroxidation) and curcumin (the active component 
of the herb tumeric), where the Sec and other Cys residues were irreversibly alkylated 
causing diminished enzymatic activity (45, 46). Other TrxR inhibitors include 
electrophiles such as gold, platinum or other metal-containing compounds that are 
considered highly potent due to their high affinity for sulfur atoms (76, 77). Several 
electrophilic compounds containing sulfur, selenium or tellurium have also been 
described as either competitive or non-competitive inhibitors of TrxR or its substrates 
such as Trx or 5,5’-dithio-bis(2-dinitrobenzoic acid) (DTNB) (77, 78, 79). Recently, the 
inhibition of TrxR by other exogenous species such as alantolactone (the active 
component of the herb Inula helenium) and sodium arsenite (NaAsO2) has been linked to 
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oxidative stress-mediated apoptosis in HeLa cells and pancreatic -cells respectively (80, 
81). 
 Most of the TrxR inhibitors previously identified are exogenous electrophilic 
compounds. However, prostaglandins, hormone-like compounds that are involved in 
inflammation, and α,β-unsaturated ketones/aldehyde products of lipid peroxidation, such 
as 4-hydroxy-2-nonenal, represent the few endogenously produced inhibitors of TrxR 
that have been studied to date. In this thesis, I investigated if TrxR was inhibited by the 
endogenous metabolite fumarate, during conditions where fumarate levels are elevated. 
In particular I was interested in adipocytes matured in high glucose, since we have 
previously demonstrated that succination is increased under these conditions (12, 13, 82). 
We have also demonstrated that adipocytes in high glucose versus normal glucose 
conditions have increased levels of oxidants such as hydrogen peroxide (unpublished 
observations). Since protein succination by fumarate is non-enzymatic and irreversible, 
this finding might identify a new endogenous inhibitor of TrxR that may in part explain 
the susceptibility of some cells to increasing oxidative stress. 
3.2 Results 
A 3T3-L1 mouse model was used to mimic fumarate-rich diabetic conditions 
where adipocytes were matured in either 5 mM or 25 mM glucose medium. Protein was 
harvested from the cells after 8 days of maturation, the cytoplasmic fraction was collected 
and special caution was taken to ensure that lipid from these cell lysates was removed 
following centrifugation. TrxR activity was measured in the cytoplasmic fractions of 
adipocyte lysates using the DTNB-reduction assay, as described in Chapter 2. The TrxR 
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activity is calculated through the use of a TrxR-specific inhibitor, sodium aurothiomalate 
(ATM). The total cellular thiol-reducing activity (samples without inhibitor present) is 
measured in parallel with the non-TrxR thiol reducing activity (samples containing TrxR 
inhibitor). TrxR activity can be calculated by subtracting the non-TrxR activity (inhibitor 
present) from the total thiol-reducing activity (inhibitor not present) and is expressed as 
the rate of molar nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per 
mg protein (mean  S.E.M). The 5 mM adipocyte group contained 3 out of 5 total 
samples that abnormally displayed higher enzymatic activities when the TrxR inhibitor 
was present, leaving TrxR activity unable to be calculated for these 3 samples. 
Unexpectedly, the average activity measured for the 5 mM adipocytes (n=2) and 25 mM 
adipocytes (n=5) were 1.19  0.16 and 3.56  0.41 nmol/min/mg, respectively (Figure 
3.1). These results represent statistically different values (*P<0.05), where adipocytes 
cultured in high glucose medium (25 mM) display a ~3-fold increase in TrxR activity 
compared to adipocytes cultured in normal glucose (5 mM). 
Levels of protein succination were analyzed using immunoblotting with an anti-
2SC antibody and increases in total succinated proteins for 25 mM adipocytes in 
comparison to 5 mM adipocytes were confirmed (Figure 3.2, 2SC panel, lanes 6-10 vs. 
lanes 1-5). TrxR1 protein levels in these adipocytes were analyzed by immunoblotting to 
correlate the measured activities of this enzyme to its abundance in each group, however 
no significant differences in band intensities were observed (Figure 3.2, TrxR1 panel). 
Levels of α-tubulin (DM1A) were also analyzed using western blotting to demonstrate 
equal amounts of protein loading per well (Figure 3.2, DM1A panel). 
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In order to produce conditions with enhanced fumarate accumulation, a cell model 
was used where 3T3-L1 mouse fibroblasts were transduced with a lentivirus containing 
fumarase (Fh) shRNA to induce Fh knockdown (Fh k/d). These were compared to a 
control group transduced with a scrambled lentivirus (i.e. fumarase was not knocked-
down). In order to ensure that the cells had sufficient incorporation of the virus, the 
plasmid also contained a puromycin resistance gene and only puromycin resistant cells 
were selected for further propagation. Once these cells were confluent for 7 days they 
were harvested and the cytoplasmic protein was collected for analysis. TrxR activity was 
measured in the cytoplasmic fractions of cell lysates using the same DTNB-reduction 
assay previously described, and the data obtained was expressed as the rate of molar 
NADPH oxidation per mg protein (mean  S.E.M). The scrambled group contained 1 
sample that exhibited higher activity when the TrxR-inhibitor (ATM) was present, 
therefore TrxR activity could not be calculated for this single instance. The average 
activity measured for the scrambled samples (n=4) and the Fh k/d samples (n=5) were 
1.99  0.89 and 3.05  0.71 nmol/min/mg, respectively (Figure 3.3). The trend for an 
increase in activity in the Fh k/d cells was unexpected, however, no statistically 
significant differences in TrxR activity were found between the two groups. 
In order to confirm that Fh k/d was successful in generating increased succination 
in these cells, SDS-PAGE coupled with immunoblotting using a polyclonal anti-2SC 
antibody was performed. The immunoblot revealed significant increases in total 
succinated proteins for Fh k/d samples in comparison to the scrambled group (Figure 3.4, 
2SC panel, lanes 6-10 vs. lanes 1-5). The immunoblot was stripped and additional 
blotting was also performed to detect levels of fumarase in both groups, confirming that 
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Fh k/d cells had significantly less levels of this protein (Figure 3.4, Fumarase panel). 
TrxR1 levels, the cytoplasmic isoform of the enzyme, were also analyzed by western 
blotting to detect any differences in the levels of the protein between these groups, 
however there were no significant differences in TrxR1 (Figure 3.4, TrxR1 panel). 
Finally, the levels of α-tubulin (DM1A) were assessed as a loading control to 
demonstrate equal amounts of protein loading per well (Figure 3.4, DM1A panel). 
3.3 Discussion 
 The thioredoxin system, composed of Trx, TrxR and NADPH, is a ubiquitous 
disulfide reducing system involved in redox regulation for various cellular processes (39, 
40, 83). TrxR is a selenoprotein with high reducing capabilities due to the reactive 
penultimate Sec residue in the active site of the enzyme. The two major isoforms of the 
TrxR include the cytoplasmic TrxR1 and the mitochondrial TrxR2. The exposed position 
and the high reactivity of the Sec residue in TrxR allow the enzyme to be readily 
modified by both endogenous and exogenous electrophiles, resulting in decreased 
enzymatic activity (45, 46, 77). In Chapter 2 of this thesis I identified a novel TrxR 
inhibitor, dimethylfumarate (DMF), which inhibits enzymatic activity due to the 
succination of several Cys containing peptides, including the active site (Figure 2.2). 
 The results of the in vitro experiments with recombinant TrxR1 and DMF served 
as a positive control and provided evidence that TrxR could be succinated leading to 
reduced enzymatic activity. The next aim of this thesis was to determine if TrxR is 
susceptible to succination by elevated levels of fumarate in cellular models. If present, 
this modification of TrxR would identify a new endogenous TrxR-inhibiting metabolite 
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that is present at elevated levels during certain disease conditions. Hereditary 
leiomyomatosis and renal cell cancer (HLRCC) leads to an accumulation of fumarate due 
to mutations or deficiencies in the enzyme fumarase, responsible for converting fumarate 
to malate (15). In the adipocyte, increased cellular metabolism due to elevated 
extracellular glucose concentrations, such as in diabetic conditions, will lead to an 
increase in ATP/ADP ratios and an accumulation of ATP. This accumulation inhibits the 
mitochondrial electron transport chain through respiratory control, and increasing the 
mitochondrial membrane potential (Δψm) and NADH/NAD
+
 ratio, leading to an 
accumulation of fumarate (13) (Figure 1.2). The cell models utilized in the described 
studies sought to mimic each of these disease conditions in order to study the effects of 
elevated fumarate on TrxR and its activity. 
 In the adipocyte model, western blotting revealed that increases in levels of total 
protein succination in cells grown in high glucose (25 mM) (Figure 3.2, 2SC panel), 
however, the levels of TrxR1 were unchanged (Figure 3.2, TrxR1 panel). TrxR activity in 
cells matured in 25 mM glucose (n=5) had significantly higher activity compared to those 
matured in 5 mM glucose (n=2) (Figure 3.1). It is worth noting that the 5 mM group 
contained 3 samples in which TrxR activity could not be measured due to issues with the 
activity assay. As mentioned in the results, the assay requires the use of a TrxR-specific 
inhibitor (sodium aurothiomalate) that allows TrxR activity to be calculated by 
subtracting the non-TrxR thiol-reduction activity from the total thiol-reduction activity. 
The 3 samples that were excluded from the reported TrxR activity (Figure 3.1) exhibited 
higher activities when the TrxR-inhibitor was present in comparison to the total activity 
(no inhibitor present), meaning TrxR activity could not be reliably calculated. In contrast 
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to the fibroblast cell model where TrxR1 protein levels and activity were not different 
between the two groups, an accurate explanation for the increase in TrxR activity for 25 
mM adipocytes is less clear. Keap1 succination by elevated fumarate levels and the 
subsequent activation of the Nrf2 pathway could explain an increase in the 25 mM TrxR 
activity due to the presence of more of this protein, however protein levels remain the 
same as in the 5 mM group (Figure 3.2, TrxR1 panel). While it is unfortunate that we 
cannot fully conclude if TrxR is endogenously succinated in adipocytes in vitro, these 
results suggest that it may not be. In the future, we hope to further examine the effects of 
enhanced fumarate conditions on TrxR in cellular models while utilizing a different TrxR 
activity assay.  
Despite the large increase in succinated proteins in the Fh k/d fibroblasts, there 
was no significant decrease in total TrxR activity when compared to scrambled controls, 
in fact the data showed a trend towards increased TrxR activity in the Fh k/d cells (Figure 
3.3). This led us to hypothesize that the cells may be compensating for the fumarate 
mediated insult by increasing the levels of antioxidant proteins such as TrxR1. However 
Western blotting revealed that protein levels of TrxR1 in these fibroblasts did not show 
any apparent changes in the fumarase-deficient cells (Figure 3.4, TrxR1 panel). Levels of 
the mitochondrial TrxR2 were not analyzed since the lysates used in the activity assays 
are cytoplasmic fractions and should contain limited mitochondrial proteins. Considering 
the lack of inhibition of enzymatic TrxR activity, as well as the equal levels of TrxR1 
protein between the scrambled and Fh k/d cells, it is appears that TrxR was not modified 
by fumarate as originally predicted. Fumarate is not as reactive as DMF, and perhaps it is 
unable to compete with the endogenous TrxR substrates, such as Trx, and induce 
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succination. It is also possible that elevated fumarate levels in Fh k/d fibroblasts lead to 
the succination of TrxR1 and the protein was rapidly turned-over. Elevated levels of 
fumarate are also known to cause succination of Kelch-like ECH-associated protein-1 
(Keap1) that, under normal circumstances, interacts with the transcription factor nuclear 
factor (erythroid-derived 2)-like-2 (Nrf2), preventing its translocation to the nucleus and 
promoting transcription of target genes (2, 7, 82). Succinated Keap-1 results in its 
dissociation with Nrf2, allowing Nrf2 to promote the transcription of various 
cytoprotective and antioxidant enzymes, including TrxR1 (84, 85, 86). Degradation of 
succinated TrxR1 and the expression of additional protein in Fh k/d cells after Nrf2 
activation could explain the relatively equal amount of TrxR activity and TrxR1 protein 
levels compared to the control samples. The assessment of TrxR activity over several 
hours, or in the presence of cycloheximide to prevent translation of new protein, may be 
required to determine if a relatively equal rate of synthesis:degradation contributed to the 
results observed.  
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Figure 3.1: TrxR activity in 5 mM vs 25 mM 3T3-L1 adipocytes. 3T3-L1 adipocytes 
were matured in 5 mM or 25 mM glucose for 8 days. Cellular thioredoxin reductase 
(TrxR) activity was measured in lysates using a DTNB reduction assay and expressed as 
the molar rate of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per 
mg protein (5 mM glucose n=2, mean ± S.E.M.; 25 mM glucose n=5, mean ± S.E.M.). 
Significant differences were found between 5 mM and 25 mM groups (*P < 0.05) with 
the 25 mM group showing a ~3 fold increase in TrxR activity. 
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Figure 3.2: Western blot of TrxR levels in 5 mM vs 25 mM 3T3-L1 adipocytes. 3T3-
L1 adipocytes were matured in 5 mM (lanes 1-5) or 25 mM (lanes 6-10) glucose for 8 
days. Protein (30 µg) was separated using 1-D SDS-PAGE and detection of 2SC was 
performed using a polyclonal anti-2SC antibody. Western blotting was also used to 
analyze protein levels of TrxR1 to determine if differences existed between the two 
groups. The levels of -tubulin (DM1A) were determined to sure equal protein loading. 
MW markers are shown in kDa on the left. 
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Figure 3.3: TrxR activity in Scrambled vs. Fh k/d 3T3-L1 fibroblasts. 3T3-L1 
fibroblasts were transfected with a scrambled lentivirus or a lentivirus containing an 
shRNA that knocks down fumarase (Fh). Cellular thioredoxin reductase (TrxR) activity 
was measured in lysates using a DTNB reduction assay and expressed as the molar rate 
of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mg protein 
(scrambled n=4, mean ± S.E.M.; Fh k/d n=5, mean ± S.E.M.). No significant differences 
between scrambled and Fh k/d groups. 
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Figure 3.4: Western blot of TrxR levels in scrambled vs Fh k/d 3T3-L1 fibroblasts. 
3T3-L1 fibroblasts were transfected with a scrambled virus (lanes 1-5) or viral shRNA 
that knocks down fumarase (Fh) (lanes 6-10). Protein (30 µg) was separated using 1-D 
SDS-PAGE and detection of 2SC was performed using a polyclonal anti-2SC antibody. 
Western blotting was also used to analyze protein levels of TrxR1 to determine if 
differences existed between the two groups, and to analyze levels of fumarase to confirm 
the knockdown in Fh k/d cells. MW markers are shown in kDa on the left and -tubulin 
(DM1A) was used as a loading control. 
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CHAPTER 4 
THE EFFECTS OF FUMARATE AND DIMETHYL FUMARATE (DMF) 
ON GLUTATHIONE PEROXIDASE
4.1 Introduction 
  Glutathione peroxidase (GPx) is a highly conserved selenoenzyme that 
contributes significant protective functions as a scavenger of damaging reactive oxygen 
species (ROS) in the cell. Due to its essential role, identifying compounds that may 
impede its normal function would prove to be very beneficial in understanding how ROS 
imbalance occurs during disease states. In contrast to thioredoxin reductase (TrxR), there 
are fewer inhibitors of GPx described in the literature, and the detailed mechanisms of 
inhibition for most of those identified are not completely understood. Recently, 
proteomic analysis has identified the succination of Cys202 of GPx1 in a fumarase (Fh) 
deficient tumor, where levels of fumarate are enhanced due to a mutation of the Kreb’s 
cycle enzyme responsible for converting fumarate to malate (16). Although the effects of 
this modification on GPx activity were not investigated, this result established that this 
enzyme could be modified by fumarate intracellularly. Although Cys202 is not in the 
active site of GPx, its ability to be succinated, and the presence of an additional Sec in 
this enzyme’s active site, provided a reason for this thesis to examine GPx activity in 
similar models where fumarate is enhanced. 
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Coenzyme A, an acyl carrier involved in the synthesis and oxidation of fatty acids 
and the oxidation of pyruvate, has also been described as a GPx inhibitor at low 
concentrations, however its mechanism of interaction with GPx is largely unknown (87). 
4-hydroxy-nonenal (HNE), an aldehyde produced during lipid peroxidation and a 
previously described TrxR inhibitor (46), has been demonstrated to cause concentration-
dependant inhibition of bovine erythrocyte GPx, which was hypothesized to be the 
caused by the modification of non-specific Cys residues (88). The exact mechanism was 
not identified, however in experiments where GPx was pre-incubated with thiols such as 
glutathione (GSH), the inhibition by HNE was not observed; proposed to be blocked by 
GSH binding to GPx (88).   
More specifically, the oxidation and subsequent inactivation of GPx has been 
described in greater detail using both endogenous and exogenous pro-oxidants. S-nitroso-
N-acetyl-D,L-penicillamine (SNAP) is an exogenous precursor to the vasodilator nitric 
oxide (NO) and causes the oxidation of Sec and Cys residues on GPx, resulting in the 
formation of either disulfide (Cys-Cys) or selenyl sulfide (Sec-Cys) bonds that cause 
inhibition of the enzyme, presumably inhibiting the catalytic cycle (89). More potent 
oxidants such as peroxynitrite, a strong nucelophilic product of nitric oxide (NO) reacting 
with superoxide (O2
-
), and 3-morpholinosydnonimine-N-ethylcarbamide, a precursor to 
the oxidant, peroxynitrite, also caused dose-dependent inhibition of GPx through 
oxidative modification of thiols or selenols (89, 90). Currently, oxidative modification 
represents the most characterized type of GPx inhibition; however this thesis aims to 
determine if irreversible succination by endogenously produced fumarate is also capable 
of inhibiting GPx in cell culture systems.  
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4.2 Results 
 In order to test the ability to modify GPx and alter its activity in vitro, 
experiments were conducted using bovine erythrocyte glutathione peroxidase (GPx, 
predominantly GPx1). The protein was incubated in 0, 10, 25, 50 and 100 µM 
dimethylfumarate (DMF, a reactive fumarate ester that we considered a positive control) 
for 1 hour at room temperature. GPx activity was measured and expressed as the molar 
rate of nicotinamide adenine dinucleotide phosphate (NADPH) oxidation per mL (mean 
 S.E.M., Figure 4.1). Statistically significant differences in GPx activity could not be 
detected, even with elevated concentrations of DMF. A similar experiment was 
performed where bovine erythrocyte GPx was incubated in 0, 5, 10, 15, 25 and 50 mM 
fumarate for 6 hours at room temperature. GPx activity was measured and expressed as 
the molar rate of NADPH oxidation per mL (mean  S.E.M., Figure 4.2). However no 
statistically significant differences in GPx activity could be detected. Several additional 
experiments were performed where the protein was treated with either DMF or fumarate 
for varying incubation times and temperatures, however no consistent reduction in 
activity was detected (data not shown). 
In order to mimic diabetic conditions, a cell model was used where 3T3-L1 mouse 
adipocytes were matured in either 5 mM or 25 mM glucose medium. GPx activity was 
measured in the cytoplasmic fractions of cell lysates and expressed as the rate of molar 
NADPH oxidation per mg protein (mean  S.E.M). The average activity measured for the 
5 mM adipocytes (n=5) and 25 mM adipocytes (n=5) were 10.60  0.64 and 7.91  0.73 
nmol/min/mg, respectively (Figure 4.3). These results represent statistically different 
values (*P<0.05), where adipocytes cultured in high glucose medium (25 mM) display an 
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average ~25% decrease in GPx activity compared to adipocytes cultured in normal 
glucose (5 mM). These results suggested that GPx activity was reduced in high glucose 
specifically, potentially as a result of succination. 
SDS-PAGE followed by immunoblotting was performed to analyze the 
differences in total succinated proteins in adipocytes matured in 5 mM vs 25 mM glucose 
(Figure 4.4, 2SC panel, lanes 1-5 vs. lanes 6-10). Western blotting was also performed to 
analyze protein levels of the two most abundant GPx isoforms, GPx1 and GPx4, and to 
correlate these levels to enzymatic activity data. There were no obvious differences in 
protein levels of either GPx1 (Figure 4.4, GPx1 panel) or GPx4 (Figure 4.4, GPx4 panel) 
for adipocytes matured in 5 mM vs. 25 mM glucose. Protein levels of α-tubulin (DM1A) 
were also analyzed using western blotting and used as a loading control (Figure 4.4, 
DM1A panel). Densitometry was performed on the immunoblots to determine the relative 
ratio of intensity of GPx1 (Figure 4.5) and GPx4 (Figure 4.6) bands normalized to DM1A 
band intensity for 5 mM or 25 mM sample, confirming that no significant differences in 
either of these proteins between the groups could be established. 
An additional cell culture model was used to examine the effects of enhanced 
fumarate accumulation on intracellular GPx; the same fibroblast model was used as for 
the TrxR experiments (see Chapter 3). 3T3-L1 mouse fibroblasts were transduced with 
fumarase knock-down (Fh k/d) lentiviral shRNA and compared to a control group 
containing a scrambled lentivirus (i.e. fumarase was not knocked-down). The virus also 
contained a puromycin resistance gene in the plasmid to ensure the selection of only the 
cells transduced with the virus. After 7 days of confluency, cellular protein was harvested 
and the cytoplasmic fractions were collected for analysis. GPx activity was measured in 
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the cytoplasmic fractions of cell lysates and expressed as the rate of molar NADPH 
oxidation per mg protein (mean  S.E.M). The average activity measured for the 
scrambled samples (n=5) and the Fh k/d samples (n=5) were 34.25  1.76 and 39.45  
2.31 nmol/min/mg, respectively (Figure 4.7). However no statistically significant 
differences in GPx activity were detected between the two groups. 
Increases in total protein succination were detected through immunoblotting in Fh 
k/d samples in comparison to scrambled controls (Figure 4.8, 2SC panel, lanes 6-10 vs. 
lanes 1-5). Decreased levels of fumarase were also detected in the Fh k/d group 
compared to the scrambled control by immunoblotting, confirming its knockdown by 
shRNA (Figure 4.8, Fumarase panel). Western blots were also probed for GPx1 to detect 
any changes in protein levels between these groups, however there were no apparent 
differences (Figure 4.8, GPx1 panel). Levels of α-tubulin (DM1A) were used as a loading 
control to demonstrate equal amounts of protein loading per well (Figure 4.8, DM1A 
panel). 
4.3 Discussion 
 My original hypothesis predicted that incubations with the highly reactive DMF 
or the endogenous metabolite fumarate would result in decreased enzymatic activity. 
However, contrary to this hypothesis, consistent changes in recombinant bovine GPx 
activities could not be observed after incubation with either DMF or fumarate in vitro, 
despite performing several experiments in each of these models. The position of the 
active site Sec and its accessibility to molecules such as fumarate or DMF may be related 
to observed lack of modification. Molecular modeling of GPx reveals that the active site 
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is located at the ends of long -helices and is surrounded by aromatic side-chains (91, 
92). Sec resides in position 47 of the 201 amino acids in the bovine GPx sequence 
(Figure 4.9), and may not be as substrate-accessible if there are some negatively charged 
amino acids nearby since fumarate contains 2 carboxyl groups. Treatment of HeLa cells 
with the cytotoxic compounds iludin S, a natural compound produced by fungi, and 
acylfulvene (AF), a semi-synthetic derivative of iludin S, caused inhibition of TrxR by 
irreversible binding to Sec but had no effect on GPx activity (92). While GPx may not be 
as reactive, this study highlights the increased exposure of the TrxR active site and 
therefore its increased susceptibility to chemical modification in comparison to the GPx 
active site. However, while I intend to pursue TrxR further, my cumulative data thus far 
suggests that fumarate may not be sufficiently reactive with either protein active site in 
vitro. 
Increases in total protein succination by immunoblotting were detected in Fh k/d 
fibroblasts compared to scrambled controls (Figure 4.8, 2SC panel), however no 
detectable decrease in GPx activity could be observed (Figure 4.7), despite the initial 
hypothesis of this enhanced endogenous fumarate model leading to the succination and 
inhibition of this selenoenzyme. The protein levels of GPx1 did not appear to change 
after western blotting analysis in the Fh k/d cells (Figure 4.8, GPx1 panel), consistent 
with the activity data. Although fumarate levels were elevated in Fh k/d cells, it is 
unlikely that succination occurred on the Sec residue of GPx, which would result in a 
decrease in enzymatic activity. In contrast, a ~25% decrease in GPx activity was detected 
in 3T3-L1 adipocytes matured in high glucose (25 mM) versus cells matured in normal 
glucose (5 mM) (Figure 4.5). In order to correlate GPx activity to the levels of this 
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protein, both the GPx1 and GPx4 isoforms were analyzed with western blotting. The 
enzymatic activity assay measures total GPx activity, where each of the isoforms 
contributes to the activity detected. Therefore, we were interested in determining GPx4 
levels for the adipocyte model because this enzyme is responsible for protection from 
lipid peroxidation and we hypothesized that GPx4 is more abundant in the lipid-rich 
adipocyte. Western blotting and densitometric analysis revealed no significant changes in 
the protein levels of GPx1 or GPx4 (Figure 4.4, GPx1/GPx4 panel), suggesting that the 
decrease in enzymatic activity detected in 25 mM cells is attributed to the chemical 
modification and inhibition of GPx as opposed to decreased amounts of this enzyme.  
Although a pronounced decrease in GPx activity was detected in an adipocyte 
model that mimics hyperglycemic conditions, and it appears it is not due to protein 
succination, the reason for decreased activity can only be speculated upon without further 
investigation. Adipocytes contain high levels of triglycerides that are subject to lipid 
peroxidation, a process that produces reactive aldehydes (e.g. HNE) that have been 
shown to covalently modify proteins (a process known as carbonylation) (93). Adipocyte 
proteins are among the most heavily carbonylated (93), and it is possible that this type of 
modification could be contributing to the observed decrease in GPx activity for 
adipocytes matured in high glucose. Unfortunately I was unable to successfully 
immunoprecipitate GPx from these samples with the antibodies available in our 
laboratory, however future work on this project may lead to the successful isolation of 
this protein for proteomic analysis and detection of possible carbonylation or succination. 
Regardless, we know that hyperglycemic conditions will lead to in an increase in 
intracellular fumarate levels as well as glucose-derived H2O2, creating a greater need for 
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antioxidants such as GPx (13, 38). Our cell model displayed a significant reduction of 
GPx activity in cells cultured in 25 mM glucose, and I believe these results confirm that 
the adipocyte GPx capability is defective during glucotoxic conditions.  
Since the assay for GPx activity provided reliable data and we did not detect 
decreases in the Fh k/d cells (Figure 4.7), it appears that fumarate alone does not modify 
the activity of GPx. As mentioned earlier in this Discussion, it is possible that other 
factors such as negative charges surrounding the Sec in the folded protein decrease 
fumarate reactivity with GPx, despite the pKa of the active site Sec. Further studies on the 
succination of other proteins containing low pKa thiols versus accessible thiols may allow 
us to further understand the factors that govern a proteins reactivity with fumarate.  
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Figure 4.1: The effects of DMF on GPx activity in vitro.  Enzymatic activity of bovine 
erythrocyte glutathione peroxidase (GPx) incubated with 0, 10, 25, 50 or 100 µM 
dimethyl fumarate (DMF) for 1 hour at room temperature (n=3). Activity is expressed as 
mean  S.E.M. of the molar rate of NADPH oxidation per mL of protein. No statistically 
significant differences were found in GPx activity between the groups. 
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Figure 4.2: The effects of fumarate on GPx activity in vitro. Enzymatic activity of 
bovine erythrocyte GPx incubated with 0, 10, 15, 25 or 50 mM fumarate for 6 hours at 
room temperature. Activity is expressed as mean  S.E.M. of the molar rate of NADPH 
oxidation per mL of protein (n=3). No statistically significant differences were found in 
GPx activity between the groups.
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Figure 4.3: GPx activity in 5 mM vs 25 mM 3T3-L1 adipocytes. 3T3-L1 adipocytes 
were matured in 5 mM or 25 mM glucose for 8 days. Cellular TrxR activity was 
measured in lysates using colorimetric GPx activity assay that utilizes glutathione (GSH), 
glutathione reductase (GR) and nicotinamide adenine dinucleotide phosphate (NADPH). 
GPx activity is expressed as the molar rate of NADPH oxidation per mL of protein (5 
mM glucose n=5, mean ± S.E.M.; 25 mM glucose n=5, mean ± S.E.M.). Significant 
differences were found between 5 mM and 25 mM groups (*P < 0.05) with the 25 mM 
group showing a ~25% decrease in GPx activity. 
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Figure 4.4: Western blot of GPx levels in 5 mM vs. 25 mM 3T3-L1 adipocytes. 3T3-
L1 adipocytes were matured in 5 mM (lanes 1-5) or 25 mM (lanes 6-10) glucose for 8 
days. Protein (30 µg) was separated using 1-D SDS-PAGE and detection of 2SC was 
performed using a polyclonal anti-2SC antibody. Western blotting was also used to 
analyze protein expression of GPx1 and GPx4 to determine if differences existed between 
the two groups using levels of -tubulin (DM1A) as a loading control. MW markers are 
shown in kDa on the left. 
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Figure 4.5: Densitometric analysis of GPx1/DM1A levels in 3T3-L1 adipocytes. 
Densitometric analysis of GPx1/DM1A levels from western blot of 3T3-L1 adipocytes 
grown in 5 mM (n=5) or 25 mM (n=5) glucose, expressed as mean ±S.E.M. No statistical 
significances were detected.
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Figure 4.6: Densitometric analysis of GPx4/DM1A levels in 3T3-L1 adipocytes. 
Densitometric analysis of GPx4/DM1A levels from western blot of 3T3-L1 adipocytes 
grown in 5 mM or 25 mM glucose, expressed as mean ±S.E.M. No statistical 
significances were detected. 
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Figure 4.7: GPx activity in scrambled vs. Fh k/d 3T3-L1 fibroblasts. 3T3-L1 
fibroblasts were transduced with a scrambled virus or viral shRNA that knocks-down 
fumarase (Fh). Cellular GPx activity was measured in lysates using a colorimetric GPx 
activity assay that utilizes glutathione (GSH), glutathione reductase (GR) and 
nicotinamide adenine dinucleotide phosphate (NADPH). GPx activity is expressed as the 
molar rate of NADPH oxidation per mL of protein (scrambled n=5, mean ± S.E.M.; Fh 
k/d n=5, mean ± S.E.M.). No significant differences were detected between scrambled 
and Fh k/d groups. 
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Figure 4.8: Western blot of GPx levels in scrambled vs. Fh k/d 3T3-L1 fibroblasts. 
3T3-L1 fibroblasts were transduced with a scrambled virus or viral shRNA that knocks-
down fumarase (Fh). Protein (30 µg) was separated using 1-D SDS-PAGE and detection 
of 2SC was performed using a polyclonal anti-2SC antibody. Western blotting was also 
used to analyze protein expression of GPx1 to determine if differences existed between 
the two groups, and to analyze levels of fumarase to confirm the knock-down in Fh k/d 
cells. MW markers are shown in kDa on the left and -tubulin (DM1A) was used as a 
loading control. 
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Figure 4.9: Bovine erythrocyte GPx protein sequence. Protein sequence from bovine 
erythrocyte GPx (P00435). Sec is underlined at position 52. 
 
 
        10         20         30         40         50
MCAAQRSAAA LAAAAPRTVY AFSARPLAGG EPFNLSSLRG KVLLIENVAS 
        60         70         80         90        100
LUGTTVRDYT QMNDLQRRLG PRGLVVLGFP CNQFGHQENA KNEEILNCLK 
       110        120        130        140        150
YVRPGGGFEP NFMLFEKCEV NGEKAHPLFA FLREVLPTPS DDATALMTDP 
       160        170        180        190        200
KFITWSPVCR NDVSWNFEKF LVGPDGVPVR RYSRRFLTID IEPDIETLLS 
QGASA
Source from <http://www.uniprot.org/uniprot/P00435> 
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CHAPTER 5 
FUTURE DIRECTIONS
Our laboratory is interested in continuing to study the effects of fumarate and 
fumarate esters on selenocysteines. The results of this thesis indicate that thioredoxin 
reductase (TrxR) and its active site Sec may be more readily succinated by dimethyl 
fumarate than glutathione peroxidase (GPx), however, neither protein Sec residue 
appeared to react with endogenously produced fumarate as readily as we initially 
predicted. To further understand this we will continue a new collaboration with Dr. 
Gianluca Miglio (University of Turin, Italy) modeling how charges and substrate 
accessibility determine the likelihood of succination, based on available crystal structures 
of Sec-containing proteins. Although the in vitro experiments from this thesis identified 
dimethyl fumarate (DMF) as a new inhibitor of TrxR through proteomic analysis, we 
hope to continue these experiments to confirm that the selenocysteine (Sec) residue is in 
fact the target of succination by the drug and the reason for the observed decrease in 
enzymatic activity.  
An immediate goal, following the completion of this thesis, is to continue with 
experiments to investigate the rapid reactivity of the DMF with cellular targets, as this 
drug is likely acting on a plethora of intracellular proteins. New efforts in our laboratory 
are underway to identify these targets and define the downstream effects of DMF. 
Ultimately it is hoped that these studies will help us better understand both the beneficial 
59 
 
actions, as well as the side effects of this drug, and facilitate the design of more targeted 
therapeutic strategies for the treatment of multiple sclerosis (MS). In our further 
investigation of the effects of DMF on TrxR, we plan to use an alternative commercially 
available activity assay (based on the reduction of insulin disulfides by reduced 
thioredoxin with thioredoxin reductase and NADPH) that will hopefully provide more 
reliable data for cellular TrxR activity in our N1E-115 model. Our goal is to determine 
the effects of DMF after 1 hour and 3 hours of treatment, while utilizing cycloheximide 
in various groups to inhibit protein synthesis. This will prevent the cells from 
synthesizing additional antioxidants such as TrxR1 in response to the insults from DMF, 
and we hypothesize that TrxR activity might be reduced. While we accept that GPx may 
not be succinated and inhibited by fumarate, the accessibility of the TrxR active site 
encourages us to pursue these planned studies with it to ensure that we have properly 
determined whether it can be modified by endogenously produced fumarate. 
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CHAPTER 6 
METHODS AND MATERIALS
Materials 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO), unless 
otherwise noted. Preparation of anti-2SC antibody was performed as described (Nagai 
2007) by Eurogentec (Fremont, CA). Polyvinylidene fluoride (PVDF) was purchased 
from GE Healthcare (Fairfield, CT). Tris Base, L-glycine, and sodium dodecyl sulfate 
(SDS) were purchased from Fisher Scientific (Waltham, MA). Tween-20 and 
CriterionTGX Precast Gels were from Bio-Rad (Hercules, CA). Thioredoxin 
Reductase 1 (TrxR1) rat recombinant protein was purchased from IMCO (Stockholm, 
Sweden) and Glutathione Peroxidase Colorimetric Activity assay were purchased from 
Cayman Chemicals (Ann Arbor, MI). 
Protein Extraction from Cells  
All samples and reagents were kept on ice while protein was harvested. The cells 
were washed three times with phosphate buffered saline (PBS). The cells were collected 
in 50 mM Tris-HCl-EDTA assay buffer and homogenized on ice using a plastic 
homogenizer. The samples were then centrifuged at 10,000 g for 15 minutes at 4C and 
the supernatant was collected. Activity assays were performed on cell lysate supernatants 
before being frozen at -70C for future experiments. 
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Measurement of Thioredoxin Reductase 1 (TrxR1) Activity in Recombinant 
Samples after Treatment with Fumarate or Dimethyl Fumarate (DMF)  
TrxR activity was measured in a clear 96-well (Corning) plate format using an 
adaptation of the method previously published (Holmgren et al., 2014). 1.5 g of rat 
recombinant TrxR1 protein (Cayman Chemicals, Ann Arbor, MI) was added to each 
sample/enzymatic in 50 mM Tris-HCl-EDTA assay buffer. Each sample was pre-reduced 
with 30-35 g of nicotinamide adenine dinucleotide phosphate (NADPH) for 5 minutes 
prior to addition of either fumarate (0-100 mM) or DMF (0-100 M). The samples were 
left to incubate for varying time periods (1-18 hours) at either room temperature or 4C. 
After incubation an additional 30-35 g of NADPH was added to each enzymatic well, 
quickly followed by the addition of 5 mM 5,5’-dithio-bis(2-dinitrobenzoic acid) (DTNB) 
to initiate the reactions.  Background/Non-enzymatic wells contained only Tris-HCl-
EDTA assay buffer with DTNB and were subtracted from the absorbance values obtained 
for the wells containing protein. Final volumes in each well totaled 200 L. Absorbances 
were measured at the 405 nm wavelength using a Tecan Safire
2
 plate reader every minute 
for 5 minutes. Data was collected using XFluor4 software (a Microsoft Excel macro).  
Measurement of Thioredoxin Reductase (TrxR) Activity in Cell Extracts  
TrxR activity was measured in a clear 96-well (Corning) plate format using an 
adaptation of the method published by (45). Sample wells contained 100-400 g of 
protein from cell lysates, 60-70 g of NADPH, and 50 mM Tris-HCl-EDTA assay buffer, 
to a final volume of 200 l. Replicate samples containing 20 M of the TrxR inhibitor 
sodium aurothiomalate (ATM) were also prepared in some cases. Positive control wells 
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contained 1.5 g of rat recombinant TrxR1, 60-70 g NADPH, and 50 mM Tris-HCl-
EDTA assay buffer. The enzymatic reactions were initiated by the addition of 5,5’-dithio-
bis(2-dinitrobenzoic acid) DTNB to each well, after which the absorbance for each well 
was immediately measured at 405 nm every minute for 5 minutes using a Tecan Safire
2
 
plate reader. Background/Non-enzymatic wells contained only Tris-HCl-EDTA assay 
buffer with DTNB and were subtracted from the absorbance values obtained for the wells 
containing protein. Data was collected using XFluor4 software (a Microsoft Excel 
macro). 
Measurement of Glutathione Peroxidase (GPx) Activity in Cell Lysates   
GPx activity was measured in a clear 96-well (Corning) plate using a Glutathione 
Peroxidase colorimetric activity assay kit (Cayman Chemicals, Ann Arbor, MI), 
according to the manufacturer’s instructions.  Sample wells contained 15-18 g of protein 
from cell lysates, 50 L co-substrate mixture (containing NADPH, glutathione, and 
glutathione reductase), and 50 mM Tris-HCl-EDTA assay buffer. Positive control wells 
contained 20 L of kit-supplied Bovine-erythrocyte GPx protein, 50 L co-substrate 
mixture, and 100 L Tris-HCl-EDTA assay buffer. Background/non-enzymatic wells 
contained 50 L co-substrate mixture and 120 L Tris-HCl-EDTA assay buffer. The 
enzymatic reactions were initiated by the addition of 20 L of cumene hydroperoxide, 
after which the absorbance for each well was measured at 340 nm (monitoring the loss of 
NADPH) each minute for 5 minutes using a Tecan Safire
2
 plate reader. Data was 
collected using XFluor4 software (a Microsoft Excel macro). 
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Western Immunoblotting  
Samples were prepared using 30 g for cell lysates with the addition of 5-7 L 
4X Laemmli loading buffer. The samples were then boiled at 95C for 15 minutes, flash 
centrifuged then loaded onto 7.5%, 12%, or 18% agarose gels and electrophoresed at 200 
V for 50-70 minutes. The protein was transferred to a PVDF membrane in transfer buffer 
at 250 mA for 100 minutes or 40 mA at 4C. The membrane was Ponceau stained then 
washed 3 times for 5 minutes in 20 mM Tris-Glycine containing % Tween20 wash 
buffer, and blocked in 5% non-fat milk or 5% bovine serum albumin (BSA) if suggested 
by antibody manufacturer. Membranes were probed using primary rabbit polyclonal anti-
2SC (1/8000). Antibodies against fumarase (Lot #1), TrxR2 (Lot #1) and DM1A tubulin 
(Lot #8) were from Cell Signaling Technology (Danvers, MA), GPx1 (Lot #GR82550-9) 
from Novus Biologicals (Littleton, CO), GPx4 (Lot #GR251529-3) from Abcam 
(Cambridge, MA), TrxR1 (Lot #CBZG021007) from R&D Systems (Minneapolis, MN). 
HRP-coupled secondary antibodies were used where appropriate; anti-mouse (Lot 
#X0328) from Vector Labs (Burlingame, CA) and anti-rabbit (Lot #26) from Cell 
signaling Technology (Danvers, MA). Pierce ECL 2 Western Blotting Substrate was 
used prior to the detection of chemiluminescence using photographic film (Denville 
Scientific, Metuchen, NJ).  ImageJ software (NIH) was used to quantify band intensity by 
densitometry. 
In-Gel Protein Digestion  
Recombinant rat thioredoxin reductase 1 (TrxR1) was incubated in the absence or 
presence of 100 M DMF for 20 hours at 37C.  Following incubation, 3 g of protein 
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was electrophoresed by SDS-PAGE as described (section above). Following 
electrophoresis the gel was stained with Coomassie Brilliant Blue for 1 hour, followed by 
de-staining in 7% acetic acid/10% methanol for 24 hours to detect TrxR protein. The 
excised gel bands cut into several smaller pieces before being washed in a 50/50% 
methanol/acetic acid solution for several days to completely remove Coomassie stain. Gel 
bands were then washed in 50mM ammonium bicarbonate in 50% acetonitrile, then 
100% acetonitrile for 5 mins and allowed to dry using a SpeedVac centrifuge. Sample 
was reduced with 10 mM dithiothreitol (DTT) was and then alkylated using 170 mM 4-
vinylpyridine (4-VP). Trypsin digestion was carried out overnight at 37C in the presence 
of 1.5 ng sequence grade modified trypsin (Promega, Madison, WI) in 50 mM 
ammonium bicarbonate. The supernatant and extracts with 5% formic acid in 50% 
acetonitrile, then 100% acetonitrile and were pooled and dried down in a SpeedVac 
centrifuge to ~20 µL. The digested samples were analyzed on a Dionex Ultimate 3000-
LC system (Thermo Scientific, Rockford, IL) coupled to a Velos Pro Orbitrap mass 
spectrometer (Thermo Scientific, Rockford, IL). 
Data Analysis  
All graphs were generated in Sigmaplot 11. Statistical analyses of the data were 
performed on SigmaStat software (Sigmaplot 11, San Jose, CA). All data were plotted as 
means ± S.E.M. An unpaired Student t test was used to test for statistical differences 
between two sets of data. A One Way ANOVA using Holm-Sidak test was used when 
comparing 3 or more sets of data. Differences were considered statistically significant at 
*
p<0.05. 
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APPENDIX A
BUFFER PREPARATIONS 
Assay Buffer 
The buffer was prepared in 250 mL stocks containing 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA. The buffer was stored at 4
o
C. 
 
Running Buffer 
One liter of 10x stock was prepared containing 250 mM Tris-HCl, 1920 mM glycine and 
10% (SDS). 
 
Transfer Buffer 
One liter of 10X stock was prepared containing 250 mM Tris-HCl, 1920 mM glycine. 
Methanol was added at 20% for transfer process. 
 
Wash Buffer 
One liter of 10X stock was prepared containing 200 mM Tris-HCl, pH 7.4. Tween-20 
was added at 0.05% to 1X was buffer. 
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APPENDIX B
LOWRY ASSAY 
Pipette the specific amounts of reagents into the microplate in the order listed. All 
samples are prepared in duplicates. 
 
Table B.1: Preparation of BSA standard curve for the Lowry assay. 
Probe 
BSA 
(µL) 
H20 
(µL) 
Copper 
Reagent 
(µL) 
Incubation Folin-
Ciocolateu 
(µL) 
Incubation 
Blank 0 20 20  60   
1 1 19 20 
  
60 
  
2 2 18 20   60   
3 3 17 20   60   
4 4 16 20   60   
5 8 12 20   60   
6 10 10 20   60   
7 20 0 20   60   
Sample 5 15 20   60   
  
Stock BSA 
Dissolve 50 mg BSA (Bovine Serum Albumin) in 10 mL deionized water=5 mg/mL 
stock/working solution 
 
20 
minutes 
at 37oC 
30 
minutes 
at 37oC 
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Working Solutions: Dilute 400 µL of 5 mg/mL stock in 600 µL water=2 mg/mL solution 
 
Table B.2: Preparation of copper reagent for Lowry assay. 
Stock Solution Working Solution 
Copper Sulfate 1% (w:v) 100 µL 
Sodium Tartrate 2% (w:v) 100 µL 
Sodium Carbonate 10% (w:v) in 0.5 M NaOH 2 mL 
 
Folin-Ciocolateu Phenol Reagent: Purchased as a 2 N stock solution. For working 
solution at 500 µL of stock solution to 5.5 mL of water 
Read absorbance at 660nm. 
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APPENDIX C
WESTERN BLOTTING 
Gel Electrophoresis 
 
1. After determining the protein content from the Lowry assay, 30-40 µg of protein was 
dissolved in water and 5 µL of Laemmli loading buffer was added. 
 
2. Boil the samples for 15 min at 95°C then flash centrifuge. 
 
3. Remove tape and comb from Bio-Rad pre cast Criterion gel and place in cassette. 
 
4. Fill the cassette tank and gel with Tris/Glycine/SDS running buffer. 
 
5. Load the samples into their individual lanes and 8 µL of marker into your lane of 
choice. 
 
6. Run the gel at 200 V for 60 min. 
 
Wet Transfer 
 
1. Remove the gel from the pre-cast and cut to size 
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2. Soak the gel in Tris/Glycine/Methanol transfer buffer for 15 min. 
 
3. Charge the PVDF membrane for ~30 sec in methanol. Soak the 2 pieces of blotting 
paper, 2 sponges, and the membrane in Tris/Glycine/methanol for 15 min. 
 
4. Assemble the transfer apparatus, starting with the black side first. Keep all materials 
soaking in transfer buffer during the assembly. 
 
5. Place the sponge flat on the black side, followed by a piece of blotting paper. Next, 
place the gel on top followed by the PVDF membrane. Roll out any air bubbles between 
the gel and membrane using a roller. Finally, put the remaining piece of blotting paper on 
top of the membrane and the sponge on top. 
 
6. Assemble the apparatus and transfer at 250 mA for 100 min or 40 mA for at least 12 
hrs. 
 
7. Remove the membrane from the apparatus and wash 3 times with nanopure water. 8. 
Place the membrane in ponceau stain for 5 min then wash with nanopure water to 
visualize the bands. Inspect the membrane for equal loading and where bubbles formed 
during the transfer process. Wash the ponceau stain off the membrane with Tris-HCl 
wash buffer. 
 
9. Block the membrane in 5% non-fat dry milk or 5% BSA for at least 1hr. 
 
Immunostaining for 2SC 
 
1. Prepare 1% milk by diluting the 5% milk 1:4 in Tris-HCl wash buffer. 
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2. Add 2SC antibody to the milk in a 1:5000 dilution. Incubate for at least 1 hr on the 
rocker. 
 
3. Pour off the antibody and wash the membrane 3 times in wash buffer for 5 min each. 
 
4. Add secondary antibody anti-rabbit to 1% milk, 1:15000 dilution and incubate for 1hr 
at room temperature. 
 
5. Pour off the milk and was the membrane 3 times for 5 min each in wash buffer.  
 
Developing 
 
1. Prepare ECL solution by adding solution B to solution A and in a 1:40 dilution. 
 
2. Add the ECL to the membrane and incubate for 5 min. Place the membrane in the 
cassette and cover with plastic wrap. 
 
3. In the dark room, place a piece of X-ray film over the membrane then develop. Inspect 
the film after it has developed and adjust the exposure times accordingly. 
 
Buffers 
 
1. Stock Running Buffer: 10X SDS – 30.3 g Tris base, 144 g glycine and 10 g SDS 
dissolved to 1 L water 
- Working solution=100mL  of 10X stock diluted to 1L water 
2. Stock Transfer Buffer: 10X transfer – 30.3 g Tris base and 144 g glycine dissolved to 
1 L water 
- Working solution=150 mL of 10X stock and 300 mL of methanol diluted to 1 L 
water 
3. Stock Wash Buffer: 10X Wash – 24.4 g Tris base dissolved to 1 L water, pH 7.4 
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- Working solution=100 mL of 10X stock and 500 µL Tween-20 diluted to 1 L 
water 
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APPENDIX D
CELL CULTURE 
3T3-L1 Cell Culture:  
3T3-L1 murine fibroblasts were purchased from American Type Culture 
Collection (Manassas, VA) and maintained in DMEM containing 5 mM glucose, 10% 
Bovine Calf Serum (Thermo Scientific), 1% penicillin/streptomycin (CellGro) at 37C 
with 5% CO2 and 95% humidity. Growth medium was replaced every 2 days. At 70-80% 
confluence the cells were removed with trypsin (Thermo Scientific), neutralized with 
excess growth medium, and collected by centrifugation at 1000 g for 5 min. The cells 
were then re-suspended in growth medium for a new passage. 3T3-L1 fibroblasts were 
seeded at a density of 100,000 cells per 10 cm
2
 petri dish. 3T3-L1 fibroblasts were 
induced to differentiate when the fibroblasts reached 24 hours post-confluence (~3-4 
days) in DMEM with 10% Fetal Bovine Serum (Atlanta Biologicals), 1% 
penicillin/streptomycin, insulin (10 μg/mL), dexamethasone (0.3 μM), 3-isobutyl-1-
methylxanthine (0.5 mM) and 30 mM glucose for 3 days. At day 0, differentiation 
medium was removed, cells were washed with PBS and maturation medium containing 5 
mM/0.3 nM or 30 mM/3 nM glucose/insulin was applied. The medium was changed 
every 2 days and the adipocytes were matured in 5 mM or 30 mM glucose for 8 days 
Cells cultured in 5 mM glucose were supplemented with 5 mM glucose daily and several 
hours prior to protein harvest to maintain glucose levels. In order to generate a model of 
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maximal succination, 3T3-L1 fibroblasts were transduced with a lentivirus containing 
either fumarase (Fh) shRNA or scrambled control shRNA as described (Frizzell et al., 
2015). The transduced cells exhibiting Fh knockdown were selected for and maintained 
in medium containing 1 μg/mL puromycin for 3 days prior to protein harvesting.  
N1E Neuronal Culture:  
N1E-115 cells (subclone N1E-115-1 neuroblastoma cells) were obtained from 
Sigma (08062511, St. Louis, MO). The cells were grown in non-differentiation medium 
(NDM, 90% DMEM (Gibco, Grand Island, NY) with 25 mM glucose, no pyruvate, 25 
mM HEPES, 4 mM Glutamine) and 10% Foetal Bovine Serum (Atlanta Biologicals, 
Atlanta, GA) in 25 cm
2
 flasks. When confluent the N1E-115 cells were differentiated into 
neurons in the presence of 2% FBS and 1.25% DMSO in DMEM. The differentiation was 
confirmed visually by phase contrast microscopy. The cells were treated with x 
dimethylfumarate for either 3 or 24 hrs prior to harvesting in 50 mM Tris-HCl-EDTA to 
assess thioredoxin reductase activity. 
 
 
 
